Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of injectable FH-006 combined with other antitumor therapies in lung cancer
CTR20254311Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Countries
- 1
01
Overview
A Phase 2 trial of FH-006 in bronchial carcinoma, non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Nov 2025; status: active.
02
Drugs
FH-006
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254311.